7 May 2024Big PharmaMuireann Bolger

Teva targets Indian pharma firm over inhaler patents

Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

INTA: ‘New normal’ for in-house counsel as budgets fall

16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.

Big Pharma

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

10 March 2026 UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.

Big Pharma

The curtain closes on three major drug disputes

11 February 2026 Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.

More features

INTA: ‘New normal’ for in-house counsel as budgets fall

Mylan withdraws defence claims against Novo in Wegovy dispute

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

Astellas blocks generic version of key urology drug until 2030

Orrick adds specialist licensing partner in Silicon Valley

GSK inks licensing deal for liver disease drug

Arnold & Porter adds tech litigator in San Francisco

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

Teva targets Indian pharma firm over inhaler patents

More on this story

Editor's picks

Editor's picks

More features